Breast Oncology Department

The Medical Oncology Department for Breast Tumors is a specialized clinical department primarily focused on the diagnosis and treatment of advanced breast cancer. It is a research ward of Peking University Cancer Hospital and currently has 20 doctors, including 6 chief physicians and 5 deputy chief physicians. There are 23 nurses: 1 chief nurse, 12 nurse supervisors, and 10 nurses; and 2 research staff: 1 associate researcher and 1 assistant researcher. The department has 33 open beds. The department focuses on comprehensive breast cancer treatment, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. It emphasizes individualized treatment based on standardized treatment, while also emphasizing clinical and translational research, and is committed to precision treatment of breast cancer guided at the molecular level. Its diagnostic and treatment capabilities enjoy a strong reputation in China. Over the past 5 years, the Department of Medical Oncology for Breast Tumors has led or participated in the completion of multiple projects, including projects of the National Natural Science Foundation of China, subprojects of the National 973 Program, the Beijing New Century Hundred-Thousand-Ten Thousand Talent Project, the Capital Medical Development Research Fund, the Special Research Fund for Doctoral Programs in Higher Education Institutions of the Ministry of Education, the Beijing Health System High-Level Talent Training Program, and major special-project topics under the National 12th Five-Year Plan. It has published more than 100 articles, including more than 50 SCI-indexed articles. Professor Li Huiping, the department director, was one of the authors of the internal medicine section of the Chinese edition of the NCCN Breast Cancer Treatment Guidelines and led the drafting of the Chinese Consensus Guidelines for Advanced Breast Cancer (CABC). As a research ward, the department undertakes a large number of international and domestic multicenter drug clinical studies. As a co-leading institution, it led the completion of the clinical study of fluzoparib combined with apatinib in advanced breast cancer with germline BRCA mutations (FABULOUS study); both drugs were approved for breast cancer indications in December 2024, and each was the first PARP inhibitor or angiogenesis inhibitor to receive approval for a breast cancer indication in China. As a co-leading institution, it completed the development of Qilu trastuzumab biosimilar, which was launched in China on July 5, 2024. It participated in the clinical study of inavolisib combined with a CDK4/6 inhibitor and endocrine therapy (INAVO120), which ranked second globally in enrollment; the drug was launched in the United States in October 2024.